SCHEMBL20948271

SCHEMBL20948271

O=C(Nc1cc2cc(-c3cccnc3)ccc2nn1)C1CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.69
GSK3B P49841 4/20 0.69
DYRK1A Q13627 3/20 0.69
MAP4K1 Q92918 2/20 0.69
ADORA2B P29275 4/20 0.53
ADORA2A P29274 2/20 0.53
HDAC3 O15379 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC2 Q92769 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.52
JAK2 O60674 1/20 0.51
TYK2 P29597 1/20 0.51
CLK1 P49759 1/20 0.50
HASPIN Q8TF76 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20948332 0.90 DYRK1A (0.73) ABL1GSK3BDYRK1AMAP4K1
SCHEMBL20947463 0.82 ABL1 (0.75) ABL1GSK3BDYRK1AMAP4K1ADORA2B
SCHEMBL10287831 0.82 ABL1 (1.00) ABL1GSK3BDYRK1A
SCHEMBL20946090 0.82 GSK3B (1.00) ABL1GSK3BDYRK1AJAK2TYK2
SCHEMBL21859617 0.82 MAP4K1 (1.00) ABL1MAP4K1
SCHEMBL20946600 0.79 GSK3B (0.73) GSK3BDYRK1A
SCHEMBL20947189 0.79 DYRK1A (0.74) ABL1GSK3BDYRK1AMAP4K1HDAC3
SCHEMBL20949489 0.79 DYRK1A (0.71) ABL1GSK3BDYRK1AMAP4K1ADORA2B
SCHEMBL20948182 0.78 GSK3B (0.70) ABL1GSK3BDYRK1AMAP4K1
SCHEMBL20947640 0.75 ABL1 (0.68) ABL1GSK3BDYRK1AADORA2BADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 ABL1 1722/4885GSK3B 19/4885DYRK1A 1/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 ABL1 1722/4885GSK3B 19/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.